Growth Hormone Induces Colon DNA Damage Independent of IGF-1 [PMID: 31002310] Laboratory literature summary: Growth Hormone Induces Colon DNA Damage Independent of IGF-1
Key indicators include: Weight loss : Patients should aim to lose at least 5% of their body weight after 12 weeks of treatment, as this is considered an indicator of effective treatment
This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects
This approach is still emerging but represents an interesting frontier for thyroid patients who want immune-modulating effects without aggressive weight loss
WEIGHT LOSS PROGRAMS Our medically guided compounded GLP-1 treatment programs are designed to support healthy, sustainable weight management by helping regulate appetite, cravings, portion control, and metabolic function
Missed dose If you forget a dose, skip the missed dose and take your usual dose the following day